A move beyond screening is required to ensure adequate healthcare response for women who experience intimate partner violence Commentary on: O'Doherty LJ, Taft A, Hegarty K, et al. Screening women for intimate partner violence in healthcare settings: abridged Cochrane systematic review and meta-analysis. BMJ 2014;348:g2913.
ContextIntimate partner violence (IPV) is an important health and human rights issue and its impact on mortality and morbidity warrants greater engagement from the health sector. 1 2 Screening for IPV has therefore been recommended, alongside screening for smoking, depressive disorders and other health-related issues, within healthcare settings. 3 It has been acknowledged that when women disclose violence perpetrated by a partner, screening should be followed by interventions such as advocacy, social support, structured clinician support and other therapeutic interventions. However, the evidence on these interventions is still limited. Screening is therefore often implemented on its own with healthcare providers informing abused women about onsite or external services.This systematic review and meta-analysis examines the effectiveness of screening for IPV within healthcare settings when not followed by an intervention. The review aims to establish the impact of screening on the identification of IPV, referral to support agencies, improvements in women's well-being and reduction in instances of further violence, while also assessing any harm that may be caused by screening.
MethodsThe authors assessed heterogeneity and publication bias, and clearly stated the question they addressed, their search strategy, study selection, assessment of study quality, data extraction and synthesis. As the review was based on a recently published Cochrane review, it adhered to recognised protocols for systematic reviews and meta-analyses from The Cochrane Collaboration and PRISMA. Eleven randomised controlled trials were eligible for inclusion, reporting on 13 027 women. The review results are reported as relative risk (RR) estimates and CIs.
FindingsSix of the studies, reporting on 2564 women, found that screening increased identification of IPV (RR=2.33, 95% CI 1.39 to 3.89), with higher rates detected in antenatal care settings (RR=4.26, 95% CI 1.76 to 10.31). No evidence was found on whether screening leads to referrals in the three studies that measured it (RR=2.67, 95% CI 0.99 to 7.20), while the two studies investigating the effect of screening on IPV 3-18 months after screening found no reductions. One study established that screening does not cause harm.
CommentaryThis review provides necessary evidence to the ongoing debate on screening for IPV in healthcare settings. 4 Despite this debate and recommendations for universal screening, O'Doherty and colleagues could only identify 11 trials of necessary quality for inclusion, with only three trials assessing referrals. This is concerning, as it has been established that women and healthcare providers only endorse screening if disclosure is followed by an ...